Skip to content
DataLookout
Menu

NCT07938463

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Timeframe: Up to 28 days.
Maximum Tolerated Dose (MTD) of TNG462
Timeframe: Up to 28 days.
MTD of Lorlatinib
Timeframe: Up to 28 days.
Recommended Phase II Dose (RP2D) of TNG462 in Combination with Lorlatinib
Timeframe: Up to 28 days.

Secondary (30)

Objective response rate (ORR)
Duration of Overall Response (DOR)
Median progression-free survival (PFS)
PFS Rate at 6 Months (PFS6)
Median Time to Treatment Failure (TTF)
Show 25 moreShow less
Median Overall Survival (OS)
Central Nervous System (CNS)-Specific PFS
Trough Concentrations of TNG462 and Lorlatinib
Central Nervous System (CNS) Adverse Event Rate
Hypercholesterolemia Rate
Hypertriglyceridemia Rate
Hepatotoxicity Rate
Interstitial Lung Disease or Pneumonitis Rate
Hematologic Toxicity Rate
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning Scores
Change from Baseline in EORTC QLQ-C30 Role Functioning Scores
Change from Baseline in EORTC QLQ-C30 Emotional Functioning Scores
Change from Baseline in EORTC QLQ-C30 Cognitive Functioning Scores
Change from Baseline in EORTC QLQ-C30 Social Functioning Scores
Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Scores (QoL)
Change from Baseline in EORTC QLQ-C30 Fatigue Scores
Change from Baseline in EORTC QLQ-C30 Nausea and Vomiting Scores
Change from Baseline in EORTC QLQ-C30 Pain Scores
Change from Baseline in EORTC QLQ-C30 Dyspnea Score
Change from Baseline in EORTC QLQ-C30 Insomnia Score
Change from Baseline in EORTC QLQ-C30 Appetite Loss Score
Change from Baseline in EORTC QLQ-C30 Constipation Score
Change from Baseline in EORTC QLQ-C30 Diarrhea Score
Change from Baseline in EORTC QLQ-C30 Financial Difficulties Score
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Scores

Arms and interventions

TNG462 plus LorlatinibExperimental

Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.

Drugs: TNG462 vopimetostat, Lorlatinib

Sites

2 sites in 1 country